Rapaflo available for benign prostatic hyperplasia (BPH)

Watson has launched Rapaflo (silodosin capsules), a selective alpha-1 adrenergic receptor antagonist, for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Rapaflo received FDA approval in October 2008.

Rapaflo is available in 4mg and 8mg capsules.

For more information call (800) 272-5525 or visit www.rapaflo.com.